Smith & Nephew announces Brian Larcombe as upcoming Senior Independent Director

– UK, London – Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, today announces in accordance with Listing Rule 9.6.11(2) R, that Richard De Schutter will retire as Senior Independent Director and Non-Executive Director, and that Ajay Piramal will retire as Non-Executive Director of Smith & Nephew plc at the conclusion of the Annual General Meeting on 10 April 2014.

Sir John Buchanan, Chairman of Smith & Nephew commented: “On behalf of the Board and management at Smith & Nephew, I would like to thank both Richard and Ajay for their significant contributions to the business. Richard, in his role as Senior Independent Director, has provided outstanding service and wise counsel to the Board through a period of significant growth and change.  Ajay has provided valuable insight into the emerging markets as we build our presence. We wish them both well in their future endeavours.”

Following the Annual General Meeting on 10 April 2014, and subject to his re-election as a Director of Smith & Nephew plc at the Annual General Meeting, Brian Larcombe will be appointed Senior Independent Director, in place of Richard De Schutter.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2013 were more than $4.3 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Comments are closed.